Granted Patent
B2
US 8,524,901 · App. 13/241,037 · Granted Sep 3, 2013
Compositions and methods for inhibition of the JAK pathway
Assignee:
Rigel Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
Claims (2)
1. A compound, or pharmaceutically acceptable salt thereof, wherein the compound is N2-(3-methoxy-5-trifluoromethyl)phenyl-5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]-2,4-pyrimidinediamine.
2. The compound of claim 1 wherein the pharmaceutically acceptable salt is N2-(3-methoxy-5-trifluoromethyl)phenyl-5-methyl-N4-[3-(phosphonooxy)methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]-2,4-pyrimidinediamine bis-sodium salt.
Assignments (2)
SECURITY INTEREST
Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 11, 2011
From: LI, HUI; HECKRODT, THILO J.; CHEN, YAN; TAYLOR, VANESSA; SINGH, RAJINDER; DING, PINGYU; YEN, ROSE
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 027214/0064 →
Continuity (4)
Provisional Application
61241630
· Sep 11, 2009
Provisional Application
61147059
· Jan 23, 2009